# Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

> **NCT02741362** · PHASE1 · TERMINATED · sponsor: **Arkansas Heart Hospital** · enrollment: 2 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Sharp's Syndrome

## Interventions

- **OTHER:** Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs
- **OTHER:** Lipoaspiration

## Key facts

- **NCT ID:** NCT02741362
- **Lead sponsor:** Arkansas Heart Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Primary Investigator no longer with institution
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741362, "Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02741362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*